Richo and Jones interviews Clive Palmer; thanks him for his generous hydroxychloroquine donation to the nation
Watch the video“Clive, we’re very grateful.” In an interview with Clive Palmer, Alan Jones teases
Watch the video“Clive, we’re very grateful.” In an interview with Clive Palmer, Alan Jones teases
In ‘Real Life’ this 10-day Ivermectin Triple Therapy reported here, appears to be a very safe, effective and inexpensive early antiviral treatment for Covid-19. Further detail from the more than 30 doctors involved in treating this patient group, will be used for a formal peer-reviewed publication.
ICU admission was significantly lower in the ivermectin group compared to controls among participants ≥40 year-old (1.2% vs 2.0, odds ratio 0.608; p=0.024).
Similarly, mortality was lower in the ivermectin group in the full group analysis (1.5% vs 2.1%, odds ratio 0.720; p=0.029), as well as in subjects ≥ 40 year- old (2.7% vs 4.1%, odds ratio 0,655; p=0.005).
Altogether, this study brings the proof of concept that an IVM-based immunomodulatory therapy improves the clinical condition of SARS-CoV-2-infected hamsters, and in clinical trials, it alleviates symptoms of COVID-19 in humans and possibly limits post-COVID-19 syndrome (also known as long COVID) via an anti-inflammatory action.
The results not only provide a structural basis for the anti-SARS-CoV-2 activity of HCQ, but also renders HCQ to be the first known drug capable of targeting LLPS.
The authors concluded based on this extensive review that ivermectin actually reduced the risk of death compared with no ivermectin (average risk ratio 0.38, 95% CI 0.19-0.73; n = 2438; I2 = 49%; moderate-certainty evidence).
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Most Covid studies have not considered days of therapy, cumulative dose, or weight-adjusted dosing. We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients. By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in Covid patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better. These data do not yet apply to hospitalized patients not on IMV. Since those with higher doses of HCQ had higher doses of AZM, we cannot solely attribute the causal effect to HCQ/AZM combination therapy. However, it is likely AZM does contribute significantly to this increase in survival rate. Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot. However, given the data presented here, the studies reporting HCQ’s effect of QTc intervals need to be re-evaluated.
British Ivermectin Recommendation Development (BIRD) is campaigning for UK approval for ivermectin to help it beat Covid. Dr Tess Lawrie wraps up their first International ivermectin conference. This is her powerful and impassioned speech.
As Head of the Department of Medical Ethics and Law, Medical Faculty, University of Maribor, Slovenia, Prof. Matjaž Zwitter presents current ethical issues around ivermectin for covid-19. His two papers on ivermectin for Covid-19, as published in Slovenian medical journal Isis and in leading newspaper Delo stirred a vivid debate among medical and lay community, hopefully leading to a change in current medical practice.
HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.
Hydroxychloroquine also can act as an oral hypoglycemic agent, as patients with diabetes taking hydroxychloroquine for rheumatologic diseases had a significant reduction in hemoglobin A1c when compared to methotrexate,40 and thus can serve to reduce hyperglycemia, a possible COVID‐19 risk factor for disease severity.
Our investigation of a large national cohort appears to support early administration (within the first 3 to 7 days of COVID-19 diagnosis) of HCQ in mild COVID-19 disease in an outpatient setting for reducing hospitalizations and deaths without any serious adverse HCQ-related effects.
If this finding is confirmed in future clinical trials, HCQ as a cheap and available drug may still play a role in a specific population with respect to reducing COVID-19 burden, particularly in resource-poor countries.
The purpose of this study was to assess the effect of oral Ivermectin treatment, which has been associated with iota-carrageenan in repeated doses through the nasal and oral topical route, on the appearance and eventual progression of COVID-19 disease in a healthy population that are exposed to it and have a higher risk of contagion of SARS-COV-2 for being health personnel from
Reductions in covid-19 deaths and infections may be possible by using ivermectin. Employing ivermectin early on may reduce the number of people progressing to severe disease. The apparent safety and low cost suggest that ivermectin could have an impact on the SARS-CoV-2 pandemic globally.
In this study, by use of DIC microscopy and NMR spectroscopy, for the first time we have decoded that HCQ specifically binds to both N-terminal domain (NTD) and C-terminal domain (CTD) of SARS-CoV-2 nucleocapsid (N) protein to inhibit their interactions with nucleic acids (NAs), as well as to disrupt its NA-induced liquid-liquid phase separation (LLPS) essential for the viral life cycle including the package of gRNA and N protein into new virions.
Source: The Palmer Foundation Men and Women of Australia I feel duty bound to bring
We conclude that two-dose ivermectin prophylaxis at a dose of 300 μg/kg body weight with a gap of 72 hours was associated with a 73% reduction of SARS-CoV-2 infection among HCWs in the following one month. Chemoprophylaxis has relevance in the containment of pandemic. This is an intervention worth replicating at other centers until a vaccine is widely available.
•TNR4 is a multidrug therapy (Ivermectin, Azithromycin, Montelukast and ASA) for COVID-19 cases.
•TNR4 increased the likelihood of recovery 3.4 times in ambulatory COVID-19 cases.
•The multidrug therapy TNR4 reduced the risk of hospitalization by 75%.
•The multidrug therapy TNR4 reduced the risk of death by 81%.
We tested the hypothesis that aerosolized HCQ sulfate (aHCQ) tolerably, safely, and rapidly achieves high respiratory tissue concentrations, while minimizing systemic toxicity.
American Journal of Medicine announces peer-reviewed early outpatient treatment protocol for Covid19 including hydroxychloroquine. Acute COVID-19 has a great range of clinical severity from asymptomatic to fatal. In the absence of clinical trials and guidelines, with hospitalizations and mortality mounting, it is prudent to deploy treatment for COVID-19 based on pathophysiological principles.
Source: Reviews in Cardiovascular Medicine Peter A. McCullough, Paul E. Alexander, Robin Armstrong, Cristian Arvinte,
Source: ivmmeta.com Figure 1. A. Random effects meta-analysis excluding late treatment. Simplified dosages are shown for comparison,
Source: Research Gate SHOUMAN WM1, HEGAZY AA2, NAFAE RM3, RAGAB ME4, SAMRA SR5, ANAS D6,
Based on this real world experience and data, nebulized hydroxychloroquine significantly improves patient outcomes and should be considered as part of the armamentaria against Covid-19.
In this study of COVID-19, for infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization
HCQ is effective for COVID-19. The chance that an ineffective treatment generated results as positive as the 187 studies to date is 1 in 5 quadrillion (p = 0.00000000000000019).
Source: PubMed Petri M, Konig MF, Li J, Goldman DW. Higher Hydroxychloroquine Blood Levels Are
Hydroxychloroquine is an effective molecule against COVID-19 infection, many RCTs and observational studies, affirmed the benefits on virological clearance.
No cases of sudden death were observed. From publication, we have treated 3,119 patients with HCQ-AZ for at least three days.
Early SMDT (sequenced multidrug therapy) should be a standard practice in high risk & severely symptomatic acute COVID-19 patients at the onset of illness.
The early use of
hydroxychloroquine decreased the improvement time
and the duration of COVID-19 detection in throat and
stool swabs.
Adjunct Prof John SkerrittDeputy SecretaryHealth Products Regulation GroupJohn.Skerritt@health.gov.auGPO Box 9848, Canberra, ACT Dear Professor Skerritt,We
Source: HCQMeta.com HCQ is effective for COVID-19 when used early: meta-analysis of 156 studies (Version
Source: Research Square. Augusto Di Castelnuovo, Mediterranea Cardiocentro, NapoliSimona Costanzo, Department of Epidemiology and Prevention,
Source: MedRxIV David M. Wiseman, Pierre Kory, Samir A Saidi, Dan Mazzucco doi: https://doi.org/10.1101/2020.11.29.20235218 Abstract BACKGROUND A recent trial (NCT04308668) found that post-exposure
Source: AAPS Online Senior Editor:Jane Orient, MD, Internal Medicine Physician, Executive Director,Association of American Physicians
Source: America’s Frontline Doctors THIS IS NOT MEDICAL ADVICE. Every situation is unique, and every
Source: swprs.org On the Treatment of Covid-19 Updated: November 16, 2020; Published: July 2, 2020 Immunological
Results obtained in the prophylaxis of Q fever indicate that chloroquine/hydroxychloroquine can be successfully used in the clinical management of infections other than malaria.
Source: Science Direct Eman Sheshah, Shaun Sabico, Rashed M. Albakr, Anmar A. Sultan, Khalaf S.
Source: Science Direct Simova I, Vekov T, Krasnaliev J, Kornovski V, Bozhinov P,Hydroxychloroquine for prophylaxis
Of the whole study group (RA and SLE), 54% used hydroxychloroquine and 44% had QTc lengths of more than 440 milliseconds. They found that the adjusted QTc length among hydroxychloroquine users was comparable to those who did not use the drug.
Source: Journal of Marine Medical Society Date of Submission 23-Aug-2020 Date of Decision 18-Sep-2020 Date
Source: Science Direct Dr. Deba PrasadDhibarMD(Assistant Professor)aDr. NavneetAroraMD(Senior Resident)aDr. ArpitKakkarDNB(Senior Resident)aDr. NeerajSinglaMD(Assistant Professor)bDr. RitinMohindraMD(Assistant Professor)bDr.
Figure 3 reported random forest for 10 studies comparing HCQ+AZM. Use of the combination HCQ+AZM was associated with 25% lower mortality risk
Source: BioSpace SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 03, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq:
Source: HCQmeta.com • HCQ is effective for COVID-19. The probability that an ineffective treatment generated
This means that zinc, low dose HCQ, and azithromycin and may prevent a large number of hospitalizations and probably deaths during the SARS-CoV-2 pandemic.
We found a higher survival rate in patients treated with hydroxychloroquine and with macrolides in our study.
This study of critically ill patients with laboratory-confirmed COVID-19 admitted to ICUs in Mexico demonstrated that age and CRP levels upon ICU admission were associated with in-hospital mortality
Author: Vladimir Zev Zelenko M.D. Source Truth stands the test of time. We are currently
Our results can assure that hydroxychloroquine used for COVID-19 patients is safe, highly tolerable, and with minimum side effects.
Hydroxychloroquine, however, was associated with a 53% reduction of being transferred to the ICU.
Ivermectin treatment was associated with lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement.
HCQ has greater efficacy if given earlier in the course of the disease. Several negative studies have been withdrawn due to methodological improprieties.
Australian MPs censored for presenting science. AUSTRALIA: North Queensland MP George Christensen, and the Member
Source: Science Direct A.J.J.LammersaR.M.BrohetbR.E.P.TheunissenaC.KosteraR.RoodcD.W.M.VerhagendK.BrinkmaneR.J.HassingfA.DofferhoffgR.el MoussaouihG.HermanidesiJ.EllerbroekjN.BokhizzoukH.VisserlM.van den BergemH.BaxnD.F.PostmaoP.H.P.Groenevelda aIsala, Zwolle, The NetherlandsbDepartment of Epidemiology and Statistics,
Source: MedRxiv. Full Study in PDF here Xabier Garcia-Albeniz, Julia Del Amo, Rosa Polo, Jose Miguel Morales Asencio, Miguel A HernanmedRxiv 2020.09.29.20203869; doi: https://doi.org/10.1101/2020.09.29.20203869 Abstract Background: There
Source: C19Study A live and ongoing index of studies from around the world documenting the use
In our study, we found hydroxychloroquine wasn’t associated with significant arrhythmia clearly relating to hydroxychloroquine so it seemed the drug was very, very safe
Therefore, Hydroxychloroquine is considered as the first‐line of COVID-19 treatment.
Source: The Lancet Summary Background Hydroxychloroquine is one of several agents being evaluated in the
In this trial, no deaths occurred related to hydroxychloroquine, and serious side effects were rare.
An Urgent Call to Depoliticize Medicine in the COVID-19 Pandemic
HCQ or CQ should be used efficiently alone or in combination with AZ to optimize the management of asymptomatic and mild cases of COVID-19.
Source: Primary Doctor Author: Colleen Huber, NMD Abstract COVID-19 disease is alleged to be caused
Source: Research Gate Conclusions Hydroxychloroquine has been shown to have consistent clinical efficacy for COVID-19
There seems to be a trend towards lower mortality among patients who received treatment with the combination of hydroxychloroquine and azithromycin than among those who did not
Dr. John Campbell Belgium, not Dutch. Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with
In this study, SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization.
HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Our data doesn’t discourage use of HCQ in inpatients with COVID-19.
Source: Science Direct Authors: LucyCatteauPharmD, PhDafi#NicolasDaubyMD, PhDbcdfi#MarionMontourcyMScafiEmmanuelBottieauMD, PhDefiJorisHautekietMScagfiElsGoetghebeurPhDfigSabrinavan IersselMD, PhDfihElsDuysburghMD, MPH, PhDafiHermanVan OyenMD, DrPHafhiChloéWyndham-ThomasMD, PhDafiDominiqueVan
Source: St Vincent’s Hospital Melbourne Healthcare workers are part of the first line of defence
Indeed, following bivariate analysis, hydroxychloroquine/azithromycin treatment was associated with a lower rate of ICU admission (P=0.008).
Source: PubMed. Author: Jean-Michel Scherrmann Scherrmann JM. Possible role of ABCB1 in lysosomal accumulation of
Source: Pandemic War room Jack Maxey and Vish Burra bring you a special edition of
Source: CBS Detroit (CBS DETROIT) – Henry Ford Health System is defending its hydroxychloroquine study showing
HCQ treatment can reduce systemic inflammation and inhibit the cytokine storm, thus protecting multiple organs from inflammatory injuries.
Source: Newsmax An Italian study found that hospitalized coronavirus patients who took anti-malaria drug hydroxychloroquine combined
Indeed, our study suggests that AZI±HCQ might have impacted COVID-19 outcome in a population of patients, optimal timing of treatment interventions to study
hydroxycholoroquine + azithromycin was associated with a 66% reduction in risk of death as compared to controls; the analysis also suggested a larger effectiveness of hydroxychloroquine in patients with less severe COVID-19 disease
Source: Medrxiv.org In this analysis of 1645 patients hospitalized with COVID-19 we find that the
Source: IC Journal Citation: Hong KS, Jang JG, Hur J, Lee JH, Kim HN, Lee
HCQ use significantly reduced the mortality rate, but this association was found only in the lowest cumulative dosage exposure group.
Source: preprints.org Scholz, M.; Derwand, R.; Zelenko, V. COVID-19 Outpatients – Early Risk-Stratified Treatment with
Source: International Journal of Infectious Diseases Highlights As of May27, 2020 there are over 1,678,843
In this study of over 6000 hospitalized patients with COVID-19 in the New York City, hydroxychloroquine use was associated with decreased mortality.
Source: Science Direct Background In our institute in Marseille, France, we initiated early and massive
Source: Vanguard Nigeria Preliminary trials on the use of chloroquine and hydroxychloroquine as prophylaxis for
Source: BioRxiv The pandemic coronavirus COVID-19 affected global health from the end of 2019 to
This study provides evidence that (hydroxy)chloroquine may be used effectively in treating moderate COVID-19 and supports larger trials.
Conclusions: In subjects free of COVID-19, we found a small increase in QTc associated with use of chloroquine, but not hydroxychloroquine. We found no increased mortality associated with use of hydroxychloroquine.
This study provides evidence that (hydroxy)chloroquine may be used effectively in treating moderate COVID-19 and supports larger trials.
Significantly higher rates of discharge home were observed in patients treated by HCQ, a novel finding warranting further confirmation in replicative studies.
None of the patients died in the studied period and only 6 have to be admitted in conventional hospitalization area.
Source: MedRxiv Abstract: The new SARS-CoV-2 infection named COVID-19 has severely hit our Health System.
Source: MedRxiv Abstract Background: While several trials are ongoing for treatment of COVID-19, scientific research
Source: ScienceDirect | PDF of full Journal Pre-Print Abstract In the context of the current
Preface: On May 22, The Lancet published a study of 96,000 COVID-19 patients stating Hydroxychloroquine
Source: Mediterranee Infection COVID-IHU #15 Version 1 du 27 Mai 2020Early diagnosis and management of COVID-19 patients: a real-life cohort study of 3,737 patients,
Source: Zendo In an open letter to MR Mehra, SS Desai, F Ruschitzka, and AN
Source: Oxford Academic – American Journal of Endimology Original unedited manuscript as PDF Abstract More
Source: FOX 2 – Detroit The FDA has warned against taking hydroxychloroquine, but President Trump says
Source: NY1 NEW YORK – Researchers at NYU’s Grossman School of Medicine found patients given
Source: Science Direct Abstract Background In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is
Source: MedRxiv Abstract Importance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs
SOURCE: The Sun UKDOCTORS in the US have claimed that a now controversial malaria drug
Source: Science Direct PhilippeGautretab1Jean-ChristopheLagierac1PhilippeParolaabVan ThuanHoangabdLineMeddebaJacquesSevestreaMorganeMailheaBarbaraDoudieraCamilleAubryaSophieAmraneaPisethSengaMarieHocquartaCaroleEldinabJulieFinanceeVera EstevesVieiraaHervé TissotTissot-DupontacStéphaneHonoréfgAndreasSteinacMatthieuMillionacPhilippeColsonacBernardLa ScolaacVéroniqueVeithAlexisJacquieriJean-ClaudeDeharojMichelDrancourtacPierre EdouardFournierabJean-MarcRolainacPhilippeBrouquiacDidierRaoultac aIHU-Méditerranée Infection, Marseille, France bAix Marseille
Source: Tech Startups Peak Prosperity April 8 Update: More doctors are now saying Hydroxychloroquine only works
No matter where you stand on how to best handle pandemic policy, Dr. Da Costa’s experience and view is worth a listen.
I’ve railed against this in the media that we are a part of, and the way that the propaganda reacts to this is, “Ignore it. Ignore all of this.” I’m saying this now because the general public has to be the one that gets angry. The general public should be furious at the way people have been treated in the country by suppression of these drugs, by that kind of website that suppresses the ability of doctors to practice medicine.
Kelly, who is the current member for Hughes in New South Wales, faced a strong backlash from segments of the media and political opponents for sharing information about the anti-malaria drug hydroxychloroquine. Kelly has since appeared at freedom rallies against mandatory vaccinations.
The judge’s finest moment may have been when he dashed the most glaring myth about ivermectin—that it is not safe, despite decades of use that shows otherwise. Noting that all drugs have side effects, Judge Fullerton listed ivermectin’s effects from a government website.
“(N)umber one, generally well tolerated; number two, dizziness; number three, pruritus; number four, nausea/diarrhea. These are the side effects for the dosage that’s being asked to be administered,” he said. “The risks of these side effects are so minimal that Mr. Ng’s current situation outweighs that risk by one-hundredfold.”
Source: FLCCC Alliance Community Author: Joyce Kamen Since January, 2020, Dr. Paul Marik, a tenured
Recently Merck issued a stern warning that seemed written by marketing, Kory says, “as it had no scientific data to support the conclusion,” that ivermectin was suddenly dangerous. Another pharmaceutical company’s CEO privately noted that “People must think Merck knows what they’re talking about because it’s their drug,” but Merck has “tremendous disincentives” to say nice things about the generic pill, as it has already spent hundreds of millions of dollars developing an oral anti-viral COVID-19 treatment, rival to ivermectin, that may be priced at $3,000 a dose.
They also restricted the use of essential off-label and generic drugs with blatant disinformation campaigns that reminded Kory of big tobacco’s efforts to hide the dangers of smoking. In effect, the public health authorities eliminated the full toolbox of essential scientific methods and drugs that doctors use every day, including the most effective early, prophylactic, and late-stage treatments for COVID-19, which were developed by frontline doctors, not pharmaceutical companies.
In the professor’s continual review of “the latest (and best) literature,” he picked up a surprising “data signal” in October from emerging studies in Latin America. ivermectin, a safe, cheap, FDA-approved anti-parasitic drug, was showing remarkable anti-viral and anti-inflammatory activity as a repurposed drug—the most powerful COVID-19 killer known to science.
Dr. Marik helplessly watched seven covid patients die needlessly after his hospital denied his use of life-saving drugs. He goes to court Thursday for the right to use his judgment to save lives.
The Palmer Foundation is the philanthropic entity owned by the Palmer family, headed by Clive Palmer.
The Palmer Foundation is a private entity that engages in charitable projects that enable better welfare of others, and society as a whole.
The foundations most recent endeavour revolves around the response to, and action on the COVID-19 Virus pandemic for the treatment of all Australians in need.
Click here to get the background on The Palmer Foundations COVID-19 Response.
No matter where you stand on how to best handle pandemic policy, Dr. Da Costa’s experience and view is worth a listen.
I’ve railed against this in the media that we are a part of, and the way that the propaganda reacts to this is, “Ignore it. Ignore all of this.” I’m saying this now because the general public has to be the one that gets angry. The general public should be furious at the way people have been treated in the country by suppression of these drugs, by that kind of website that suppresses the ability of doctors to practice medicine.
Kelly, who is the current member for Hughes in New South Wales, faced a strong backlash from segments of the media and political opponents for sharing information about the anti-malaria drug hydroxychloroquine. Kelly has since appeared at freedom rallies against mandatory vaccinations.
The judge’s finest moment may have been when he dashed the most glaring myth about ivermectin—that it is not safe, despite decades of use that shows otherwise. Noting that all drugs have side effects, Judge Fullerton listed ivermectin’s effects from a government website.
“(N)umber one, generally well tolerated; number two, dizziness; number three, pruritus; number four, nausea/diarrhea. These are the side effects for the dosage that’s being asked to be administered,” he said. “The risks of these side effects are so minimal that Mr. Ng’s current situation outweighs that risk by one-hundredfold.”